German market leader within a few years

Business development

M1 has a clear growth strategy within the established business model. Since the opening of our first location in Berlin in 2012, we have continuously developed. Today, M1 is the market leader in Germany and has started the international expansion. In the coming years we will open numerous new locations in Germany and roll out the successful their model internationally. We see great potential in practically every country in Western Europe and beyond. After all, the markets for cosmetic surgery are very fragmented and prices are too high.

In addition, we see potential in other areas of aesthetic and plastic medicine and, from a medical point of view, the demand for specialization. That, we want to take advantage of.


Outlook: targets by the end of 2025

Growth targets

  • to operate approx. 75 - 100 M1 Med Beauty outpatient clinics
  • to be a leading lifestyle brand in aesthetic medicine
  • to be internationally known with our own brand for medical cosmetics

 

Latest news

| Investor News

  • 20th Location outside Germany opened in Bucharest, Romania
  • Break-even expected for foreign locations within the next 12 months
  • Subsidiary established in the USA: Market entry into the world's largest market for beauty medicine expected in 2024

| Investor News

  • Group revenue increases by around 9% to EUR 150.8 million in the first half of 2023 (previous year: EUR 138.7 million)
  • Group EBIT increases by over 60 % to EUR 7.3 million (previous year: EUR 4.5 million)
  • Beauty segment: sales increase of more than 33% to EUR 37.2 million and EBIT margin above 20 % for the first time

M1 Kliniken AG announces figures for the first quarter of 2023. Accordingly, the consolidated group revenue of the M1 Group increased by around 21% to EUR 76.8 million in the first quarter (previous year: EUR 63.5 million).

| Ad-hoc news

The Management Board of M1 Kliniken AG today resolved to repurchase up to 1,500,000 shares of the Company in a maximum total volume of EUR 10,800,000.00 (excluding incidental acquisition costs).